The impact of dendritic cell-tumor fusion cells on cancer vaccines - past progress and future strategies

摘要: Dendritic cells (DCs) are potent antigen-presenting that can be used in cancer vaccines. Thus, various strategies have been developed to deliver tumor-associated antigens via DCs. One strategy includes administering DC-tumor fusion (DC-tumor FCs) induce antitumor immune responses patients. However, clinical trials using this fallen short of expectations. Several factors might limit the efficacy these anticancer To efficient and enhance potential benefits, FC-based vaccines require manipulations improve immunogenicity for both DCs whole tumor cells. This review addresses recent progress improving outcomes